Bristol Myers Squibb (BMY) has entered a strategic collaboration with Pathos AI and Tempus to integrate artificial intelligence and patient data into its neuroscience research pipeline. Announced on October 23, 2026, the deal grants BMY three-year exclusive rights to utilize the Pathos Foundry platform for Alzheimer's and other neurological programs, leveraging a de-identified longitudinal dataset covering hundreds of thousands of patients. Under the terms of the agreement, Pathos AI will license this Tempus dataset under a five-year contract valued at 55 million US dollars. The collaboration aims to enhance disease biology examination, test research hypotheses, and facilitate more targeted, adaptive clinical trials. Additionally, Bristol Myers Squibb is leading Pathos AI's 237 million US dollar Series E financing round to support the expansion of the Foundry platform and its clinical-stage oncology pipeline. The strategic update positions BMY to improve candidate selection, patient identification, and trial execution within its broader research and development portfolio. While the immediate stock price was noted at 56.23 euros on November 6, 2026, the long-term commercial payoff for Bristol Myers Squibb depends on whether this AI integration successfully accelerates drug development and yields tangible earnings improvements through regulatory milestones.